ESH MM 2018 | Future treatment combinations for myeloma

Kenneth Anderson

Multiple myeloma (MM) therapy has evolved rapidly in recent years, and is showing no sign of slowing. Here, Kenneth Anderson, MD, from Harvard Medical School, Boston, MA, discusses interesting future treatment combinations from the European School of Haematology (ESH) International Conference on MM 2018. Dr Anderson highlights a number of approaches and devlopments, including the upcoming MMRF MyDRUG trial that will utilize genomic profiling and combination treatments.

Share this video